61 results about "Mammary tumor" patented technology

A reconstituted human breast tumor model is disclosed. The model, which is incorporated into mice, provides actual tumors that arise spontaneously, thereby mimicking naturally occurring breast cancer. The tumors are genetically human, because they arise from human mammary tissues that develop from human mammary epithelial cells implanted into host mice. Prior to implantation, the mammary epithelial cells are genetically modified to contain a recombinant human oncogene and an SV40 early region.

An imaging, guidance, planning and treatment system integrated into a single unit or assembly of components, and a method for using same, that can be safely and effectively deployed to treat prostate cancer in all medical settings, including in a physician's office or in an outpatient setting. The system utilizes the novel process of Radio-Frequency Electrical Membrane Breakdown (“EMB” or “RFEMB”) to destroy the cellular membranes of unwanted or cancerous tissue without denaturing the intra-cellular contents of the cells comprising the tissue, thereby exposing tumor antigens and other intra-cellular components which can have an immunologic effect on local or distant cancerous tissue, with or without the addition of immunologic adjutant drugs. The system preferably comprises at least one EMB treatment probe 20, at least one trackable biopsy needle 200, at least one trackable anesthesia needle 300, and at least one controller unit for at least partially automating the treatment process.

A method for the diagnosis of breast cancer using an anti-LAT1 monoclonal antibody. Among intraductal breast neoplastic lesions, duct carcinoma in situ, which is malignant, expresses LAT1 at a significantly high level, as compared to intraductal breast papilloma, which is benign. An anti-LAT1 monoclonal antibody is useful for the discrimination between these two lesions. Further, LAT1 is expressed at a high level in most of triple negative infiltrating carcinomas, which are negative for all of ER, PgR, and HER2 that are conventional molecular targeting markers for breast cancer. Therefore, LAT1 can be used as a novel molecular targeting marker for the triple negative breast cancer.

A reconstituted human breast tumor model is disclosed. The model, which is incorporated into mice, provides actual tumors that arise spontaneously, thereby mimicking naturally occurring breast cancer. The tumors are genetically human, because they arise from human mammary tissues that develop from human mammary epithelial cells implanted into host mice. Prior to implantation, the mammary epithelial cells are genetically modified to contain a recombinant human oncogene and an SV40 early region.

Reconstituted human breast tumor models are disclosed. The models, which are incorporated into mice, provide actual tumors that arise spontaneously, thereby mimicking naturally occurring breast cancer. The tumors are genetically human, because they arise from human mammary tissues that develop from human mammary epithelial cells implanted into host mice. Prior to implantation, the mammary epithelial cells are genetically modified to contain either: (a) a recombinant human oncogene and an SV40er; or (b) a recombinant human oncogene, a transgene or shRNA that inhibits the p53 pathway, and a transgene or shRNA that inhibits the Rb pathway.

Disclosed is a Chinese medicinal preparation for treating mammary gland hyperplasia and tumor, which is prepared from the following raw materials: drynaria, pangolin scales, rhizoma Gastrodiae, duchesnea, pseudo-ginseng powder, prunella spike, curcuma root, ganoderma lucidum, astragalus root, Chinese angelica root, root of herbaceous peony, dandelion, oyster, cactus, myrrh, cow-bezoar and barbat skullcap.

The present invention belongs to the field of Chinese medicine technology, and is especially mastosis treating tablet and its preparation process. The mastosis treating tablet is prepared with oyster seaweed, kelp, spatholobus stem, epimedium and other Chinese medicinal materials. It is used in treating hyperplasia of mammary glands, mammary tumor, mastalgia and other mastosis. Compared with available similar medicine, the mastosis treating tablet has small dosage.

The invention discloses a Chinese medicinal herb for treating breast neoplasms, which consists of medicaments for external use and medicaments for oral administration. In the Chinese medicinal herb, the medicaments for external use are taken as main materials while the medicaments for oral administration are taken as subsidiary materials; the medicaments for external use are prepared by grinding and mixing the following 18 Chinese medicinal herbs: 1 to 10g of brimstone, 1 to 10g of red orpiment, 1 to 10g of yellow lead, 2 to 15g of marble, 1 to 10g of galalith, 1 to 10g of rhizoma drynariae, 1 to 10g of liquoric root, 1 to 10g of peristrophe baphica, 1 to 10g of leonurus heterophyllus, 2 to 15g of Chinese fevervine herb, 2 to 15g of rhynohophylla, 1 to 10g of memorialis hirta, 2 to 15g of long-stalked kadsura root, 1 to 10g of paniculate swallowwort root, 1 to 10g of cynanchum amplexicaule, 1 to 10g of Chinese forgetmenot root, 1 to 10g of cotton rose hibiscus leaf and 1 to 10g of grain husk leaf; and the medicaments for oral administration are prepared by decocting 2 to 15g of Chinese angelica, 1 to 10g of akebia stem, 2 to 15g of astragalus, 2 to 15g of October clematis stem, 3 to 20g of root of straight ladybell, 3 to 20g of apricot-leaved adenophora root, 1 to 10g of swordlike atractylodes rhizome, 1 to 6g of ricepaperplant pith and 2 to 15g of liquoric root in water. The suppression powder for the breast neoplasms of the invention has the characteristics of short treatment period, good treatment effect, no side effect and relapse prevention, and simultaneously, patients have no pain during treatment, and the treatment cost is low.

The invention relates to a breast pad used for installation of an electrode, a breast pad assembly comprising a breast pad, and a mammary tumor detection device comprising a breast pad assembly. The breast pad comprises a C-shaped elastic pad used for the installation of the electrode, and the axial side surface of the elastic pad is provided with a clamping protrusion and a clamping hole. After the clamping protrusion is matched with the clamping hole, the elastic pad is changed from the shape of C into the shape of a horn. The breast pad, the breast pad assembly, and the mammary tumor detection device are disposed between the breast and the bra, and therefore the good contact of the electrode with the breast can be guaranteed, and the user can wear the normal brad by using the mammary tumor detection device.